Long-term follow-up after ovarian borderline tumor: Relapse and survival in a large patient cohort

Lenhard, Miriam; Mitterer, Stefanie; Kümper, C.; Stieber, P.; Mayr, Doris; Ditsch, Nina; Friese, Klaus; Burges, Alexander

doi:10.1016/j.ejogrb.2009.04.031

Cited by 71 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these cases, large peritoneal biopsies and deperitonealisation of all suspicious regions are required [32]. Obviously, a close follow-up is required in women who undergo a conservative treatment [33]. Authorship S.F.…”

Section: Discussionmentioning

confidence: 99%

Accuracy of intra-operative frozen section in the diagnosis of borderline ovarian tumors and clinical impact of underdiagnosis

Ferrero¹,

Morotti²,

Venturini³

et al. 2018

Oncol Res Rev

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Accuracy of intra-operative frozen section in the diagnosis of borderline ovarian tumors and clinical impact of underdiagnosis

Ferrero¹,

Morotti²,

Venturini³

et al. 2018

Oncol Res Rev

View full text Add to dashboard Cite

show abstract

“…Compared with patients with epithelial ovarian cancer, patients with BOT are younger, with prevalence of the disease by age being 10 years younger. BRCA gene mutations are rarely found in these patients and most of the patients are in the early stages of the disease at the time of diagnosis (stage I in 75% of patients) (4). Primary infertility, ovulation-induction drugs, family history of ovarian cancer, nulliparity and smoking increase the risk of Micro papillary pattern is a specific pathological characteristic occasionally found in S-BOT.…”

Section: Epidemiologymentioning

confidence: 99%

Diagnosis and Management of Borderline Ovarian Tumor Based on the Iranian Guidelines

Akhavan¹,

Mousavi²,

Alibakhshi³

2016

Obstet Gynecol Cancer Res

View full text Add to dashboard Cite

Borderline ovarian tumors (BOT) consist of epithelial ovarian lesions that express cytological features of malignancy, but unlike malignant ovarian tumors, do not show obvious stromal invasion. The tumor incidence is between 1.8 and 4.8 per 100,000 females per year. The two major groups of BOT include serous BOT (S-BOT) and mucinous BOT (M-BOT). S-BOTs are divided into two categories: tumors limited to ovary and tumors spreading outside the ovary. M-BOTs are divided into two categories. The more common type is intestinal that constitutes 85% of cases and the second type is endocervical or Mullerian. Mullerian M-BOTs is bilateral in 40% of cases, while it is accompanied by pelvic endometriosis in 20-30% of patients. Microscopic examination by intraoperative frozen section is necessary because macroscopic view of ovarian tumors alone is not reliable. It is better to perform conservative surgery until the final report is ready in patients who wish to preserve their fertility. It is hard to differentiate them based on clinical characteristics. Values of tumor markers including CA125, CA19-9 and CEA in diagnosis of BOT are confirmed. Standard treatment of BOT is surgery as is the case with invasive epithelial ovarian cancer. In the majority of patients referred for BOT, since there is no suspicion of malignancy, staging is not performed. In these cases, making decision to repeat surgery and staging depend on factors such as the type of histology, abdominal exploration results in the previous surgery and probability of the presence of residual tumor.

show abstract

“…BOTs are viewed as an intermediate state between benign cystadenomas and adenocarcinomas. BOTs represent 15-20% of epithelial ovarian carcinomas (EOC), and 80% of them are diagnosed during the early stages of development [2,3]. Most women are diagnosed around 40 years of age but this can vary depending on ethnicity and geography [4].…”

Section: Introductionmentioning

confidence: 99%

In Ovo Progression of Borderline Ovarian Tumors

Meynier¹,

Undurraga²,

Jc³

et al. 2017

J Oncol Transl Res

View full text Add to dashboard Cite

Objective: Borderline ovarian tumors (BOTs) are generally considered to be non-invasive tumors with low malignancy potential. However, studies show that BOTs have the ability to progress to low-grade carcinomas and gain the potential to invade surrounding tissue and to metastasize. Here, we investigate whether a patient derived serous BOT (SBOT) could progress in low-grade serous carcinoma (LGSC) through in vitro and in ovo characterization.Methods: Ovarian cancer cell line from a SBOT, named OCAM, were isolated and characterized by PCR, migration assay and chick chorioallantoic membrane (CAM) assay.Results: OCAM cells express carcinoma characteristics and form a tumor in CAM. Moreover, OCAM cells get into membrane of chicken suggesting invasive properties. Conclusion:SBOTs could a precursor of LGSC involving consequences in adaptation of treatment provided by clinician.

show abstract

Long-term follow-up after ovarian borderline tumor: Relapse and survival in a large patient cohort

Cited by 71 publications

References 22 publications

Accuracy of intra-operative frozen section in the diagnosis of borderline ovarian tumors and clinical impact of underdiagnosis

Accuracy of intra-operative frozen section in the diagnosis of borderline ovarian tumors and clinical impact of underdiagnosis

Diagnosis and Management of Borderline Ovarian Tumor Based on the Iranian Guidelines

In Ovo Progression of Borderline Ovarian Tumors

Contact Info

Product

Resources

About